Alkem Laboratories Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹4,001Cr
- +17.2% YoY
- Net profit
- ₹779Cr
- +11% YoY
- Margin
- 23%
- +1 pp YoY
Guidance rank: #61 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
India business growth: Expected to continue strong with at least 100-150 bps outperformance over the Indian Pharmaceutical Market (IPM) growth of ~8-8.5% for H2 FY26 and FY27. - Domestic market remains core; strategic initiatives support sustained momentum. - Non-U.S. Alkem expects continued strong growth across India, U.S., and key international markets supported by new product launches. - India business is forecasted to outperform the market by 100 to 150 basis points with a double-digit growth outlook for FY27. - U.S.
From Alkem Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business growth: Expected to continue strong with at least 100-150 bps outperformance over the Indian Pharmaceutical Market (IPM) growth of ~8-8.5% for H2 FY26 and FY27.
- Domestic market remains core; strategic initiatives support sustained momentum.
- Non-U.S. export markets projected to grow at high teens to around 20% annually.
- U.S. CDMO plant: Operationally just started; expected revenue ramp-up to INR300 crores annual run rate in 12-18 months.
- MedTech business: Break-even anticipated in FY28, with moderate operational expenses during ramp-up.
2 more points from Alkem Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alkem Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The U.S. CDMO plant recently became operational, with ongoing ramp-up expected to reach full capacity and INR 300 crores revenue run-rate in 12 to 18 months. Future expansion investments will be considered based on opportunity and demand.
- Medtech business is in investment phase, with planned expenses on product filings and approvals for new markets; breakeven expected by FY '28.
- India remains the core market with continuous brand/market investments; strategic acquisitions considered when right opportunities emerge.
2 more points from Alkem Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alkem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The newly operational U.S. CDMO plant has just started and has an estimated order book expected to generate around INR 300 crores in revenue over the next 12 to 18 months.
- Current quarterly revenues from the U.S. CDMO business are around INR 15-20 crores, with operating expenses at approximately INR 50 crores per quarter as ramp-up continues.
- Management is closely monitoring the order book and plant output, with potential for further investment if demand warrants it.
2 more points from Alkem Laboratories Ltd's call on order book
Create a free account to keep reading this call
Alkem Laboratories Ltd — Quarterly revenue & net profit
Alkem Laboratories Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 4,001 | 3,415 | +17.2% | 3,371 | +18.7% |
| Operating profit (EBITDA) | 921 | 753 | +22.3% | 739 | +24.6% |
| Operating margin | 23% | 22% | +1 pp | 22% | +1 pp |
| Profit before tax | 896 | 780 | +14.9% | 771 | +16.2% |
| Net profit (PAT) | 779 | 702 | +11% | 668 | +16.6% |
| EPS (₹) | 63.99 | 57.60 | +11.1% | 55.56 | +15.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹3.7K Cr, net profit ₹521 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alkem Lab's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alkem Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alkem Laboratories Ltd Q2 FY26 results?
India business growth: Expected to continue strong with at least 100-150 bps outperformance over the Indian Pharmaceutical Market (IPM) growth of ~8-8.5% for H2 FY26 and FY27. - Domestic market remains core; strategic initiatives support sustained momentum. - Non-U.S. Alkem expects continued strong growth across India, U.S., and key international markets supported by new product launches. - India business is forecasted to outperform the market by 100 to 150 basis points with a double-digit growth outlook for FY27. - U.S.
What is Alkem Laboratories Ltd share price analysis?
Alkem Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 27.9 with a market cap of ₹68,110 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alkem Laboratories Ltd planning capital expenditure?
The U.S.
Keep Alkem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.